{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:30:13Z","timestamp":1790875813459,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:13:20Z","timestamp":1750490000000},"page":"2968-2969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beyond the bench: Revitalizing ataluren development for rare genetic disorders"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-4487","authenticated-orcid":false,"given":"Valentino","family":"Bezzerri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.06.002_bib1","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/overview\/translarna-epar-medicine-overview_en.pdf."},{"key":"10.1016\/j.ymthe.2025.06.002_bib2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14656566.2017.1359255","article-title":"Ataluren in cystic fibrosis: development, clinical studies and where are we now?","volume":"18","author":"Zainal Abidin","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.06.002_bib3","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s00415-023-11687-1","article-title":"Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis","volume":"270","author":"Mercuri","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymthe.2025.06.002_bib4","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/j.ymthe.2025.03.045","article-title":"A precision medicine approach to primary immunodeficiency disease: Ataluren strikes nonsense mutations once again","volume":"33","author":"Lentini","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.002_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.06.002_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2156-9-83","article-title":"Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues","volume":"9","author":"Zetoune","year":"2008","journal-title":"BMC Genet."},{"key":"10.1016\/j.ymthe.2025.06.002_bib7","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41467-022-30080-6","article-title":"Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.06.002_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13035","article-title":"Haematopoietic stem cells require a highly regulated protein synthesis rate","volume":"509","author":"Signer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.06.002_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:11:34Z","timestamp":1782958294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625004538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001625004538"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the bench: Revitalizing ataluren development for rare genetic disorders","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.045","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}